CytoMed Therapeutics Announces Upcoming AGM
TipRanksApr 24 17:28 ET
Express News | CytoMed Therapeutics Diversifies Into Regenerative Medicine After Research Collaboration With Singapore's Sengkang General Hospital
Moomoo 24/7Mar 20 08:46 ET
CytoMed Diversifies Into Regenerative Medicine After Research Collaboration With Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company that focuses on utilizing its licensed propriet
AccesswireMar 20 08:30 ET
Express News | CytoMed Therapeutics Has Obtained Board Approval To Launch, Pilot Program To Isolate And Cryo-Store Peripheral Blood Mononuclear Cells For And As A Reward To Loyal Shareholders Of CytoMed On Complimentary Basis, The Program Will Commence On June 1, 2024
Moomoo 24/7Mar 18 06:16 ET
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to
GlobeNewswireMar 18 06:00 ET
CytoMed Therapeutics Limited Announces Research Collaboration With Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to
GlobeNewswireMar 4 05:00 ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersNanoString Technologies (NASDAQ:NSTG) stock moved upwards by 26.9% to $0.15 during Friday's pre-market session. The company's market cap stands at $7.0 million. TC BioPharm (Holdings) (NASDAQ:T
BenzingaFeb 9 08:06 ET
OGEN, SSP and ZENV Among Mid-day Movers
Seeking AlphaFeb 7 12:58 ET
Tenax Therapeutics, Equillium Among Healthcare Movers
Seeking AlphaFeb 7 10:00 ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersSocietal CDMO (NASDAQ:SCTL) shares moved upwards by 23.4% to $0.57 during Wednesday's pre-market session. The market value of their outstanding shares is at $59.7 million. Apollomics (NASDAQ:AP
BenzingaFeb 7 08:06 ET
CytoMed Therapeutics Receives Patent in Malaysia for Its Prospective Cancer Therapy
CytoMed Therapeutics (GDTC) said Monday that its chimeric antigen receptor gamma delta T cell technology targeting solid and hematological tumors has been approved for a patent by the Intellectual Pro
MT NewswiresJan 29 11:37 ET
Express News | Cytomed Therapeutics Announced That The Intellectual Property Corporation Of Malaysia Has Granted A Patent For Its Chimeric Antigen Receptor Gamma Delta T Cell Technology, Which Targets Solid And Hematological Tumors
Moomoo 24/7Jan 29 07:23 ET
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
The Company now has exclusive rights to a Malaysia, US and China patent.
GlobeNewswireJan 29 07:00 ET
Athira Pharma, Sera Prognostics Among Healthcare Movers
Seeking AlphaJan 11 09:59 ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersCyclo Therapeutics (NASDAQ:CYTH) stock rose 34.1% to $2.2 during Wednesday's after-market session. The market value of their outstanding shares is at $50.0 million. Cingulate (NASDAQ:CING) shar
BenzingaDec 27, 2023 16:31 ET
One CytoMed Therapeutics Insider Raised Stake By 46% In Previous Year
Yahoo FinanceDec 21, 2023 10:44 ET
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-
BenzingaDec 5, 2023 07:34 ET
Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target
Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:GDTC) with a Speculative Buy and maintains $5 price target.
BenzingaDec 4, 2023 09:57 ET
CytoMed Therapeutics Limited Reports 1H Results
Seeking AlphaNov 17, 2023 10:45 ET
CytoMed Therapeutics Reports 1H 2023 Financial Report And Provides Corporate Update; Cash And Cash Equivalents: As Of June 30, 2023, The Company Had Cash And Cash Equivalents Of $7.72M
Financial Results for the Six Months Ended June 30, 2023Net Loss: For the six months ended June 30, 2023, the Company's unaudited net loss amounted to S$1.16M ($860,695) excluding expenses related to
BenzingaNov 17, 2023 09:24 ET
No Data
No Data